Ildong Pharmaceutical Launches New Hyaluronic Acid Filler Product 'Hyalive Series'
Non-Animal Derived High-Purity Hyaluronic Acid Raw Material
Composed of 4 Types Based on Particle Size
[Asia Economy Reporter Lee Gwan-joo] Ildong Pharmaceutical announced on the 16th that it has launched a new hyaluronic acid filler product, the ‘HYALEVE series’.
?
The ‘HYALEVE series’ is a medical device for tissue restoration and wrinkle improvement that contains non-animal, sterile hyaluronic acid derivatives obtained through microbial fermentation manufacturing methods, along with the local anesthetic lidocaine for pain relief. The product lineup is composed of four types?▲HYALEVE No.1 ▲HYALEVE No.2 ▲HYALEVE No.3 ▲HYALEVE No.4?differentiated by gel particle size to broaden the range of choices.
HYALEVE uses a high molecular weight, high viscosity hyaluronic acid derivative of 3 million Da (Dalton, a unit of atomic and molecular mass), and clinical trials have confirmed its excellent volume and duration. Additionally, by applying the ‘Multi-Mixed Crosslinking Technology (MMCT method)’ owned by Ildong Hyaltech, a hyaluronic acid business affiliate of Ildong Holdings, the bonding efficiency and uniformity between hyaluronic acid and the crosslinking agent were enhanced to secure the filler’s quality and durability.
Furthermore, utilizing a patented washing method, residual foreign substances such as crosslinking agents remaining after the manufacturing process were effectively removed, increasing the purity and safety of the hyaluronic acid raw material. The syringe features a special butterfly-shaped double grip. Through ergonomic design, it provides a stable grip and facilitates easy manipulation during procedures, allowing uniform pressure control when injecting the filler.
Hot Picks Today
Samsung Electronics Introduces New "Special Performance Bonus" for Semiconductors, Paid Entirely in Company Shares
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- Hyundai Mobis, Key Supplier for Hyundai’s Atlas, Target Price Raised [Click eStock]
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
An Ildong Pharmaceutical official explained, “We plan to carry out marketing of ‘HYALEVE’ mainly targeting the aesthetic market, including dermatology and plastic surgery, and continue to promote the development of various raw materials and products related to hyaluronic acid in cooperation with Ildong Hyaltech.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
